Chemotherapy outcomes following immunotherapy failure in advanced squamous cell carcinoma of the head and neck

Immune checkpoint inhibitors (ICIs) alone or with chemotherapy (CT) is a new standard of care in first-line recurrent, metastatic squamous cell carcinoma of the head and neck (SCCHN). With the growing use of ICIs in this setting, response rates to second-line CT are now being explored. We investigated whether prior ICI therapy associated with more favorable outcomes for SCCHN patients on CT, as ICIs may produce lasting immunomodulation that may influence subsequent CT benefit.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Management of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Source Type: research